EZH2 and acute myeloid leukemia: Based on the above, researchers began exploring the combination of EZH2 inhibitors and DNA-damaging cytotoxic agents in AML treatment, and their findings confirmed that EZH2 inhibition could enhance DNA damage by cytotoxic drugs (such as doxorubicin and cytarabine) (Fujita et al., 2018; Porazzi et al., 2022).